01—Abstract
Summary
Summary of the 8-K filed November 7, 2025. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) filed a Current Report on Form 8-K on November 7, 2025 to disclose, via Exhibit 99.1, its press release dated November 6, 2025 announcing the pricing of two convertible senior notes offerings.
The Company priced $650.0 milliona aggregate principal amount of 0% convertible senior notes due 2031 (the 2031 Notes) and $650.0 million aggregate principal amount of 0.875% convertible senior notes due 2032 (the 2032 Notes), for a total of $1.3 billion before the initial purchasers' 13-day option to buy up to an additional $100.0 million of each series. The offering is being sold only to qualified institutional buyers under Rule 144A. Both series have an initial conversion rate of 11.4683 shares per $1,000 principal amount, equal to an initial conversion price of approximately $87.20 per share, a conversion premium of approximately 27.5% over the $68.39 closing price on November 6, 2025.
The Company will settle conversions in cash and/or shares at its election. The Company expects the net proceeds to be approximately $1.274 billionb (or approximately $1.47 billion if the option is exercised in full). It expects to use about $182.7 million for capped call transactions, with a cap price of $136.78 per share (a 100% premium to the reference price), and about $1.020 billion to repurchase portions of its existing 0.25% convertible notes due 2027 and 1.00% convertible notes due 2028 through privately negotiated transactions, with approximately $1.019 billion in cash expected to be paid including accrued interest.
The remainder is intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and future note repurchases. The filing notes that the note repurchases and related hedging activity by counterparties could affect the market price of Halozyme's common stock and the Convertible Notes, and could result in a higher effective conversion price. The Company expects the offering to close on November 12, 2025, subject to customary closing conditions.
02—Key points
Key Highlights
- Priced $650.0 million of 0% convertible senior notes due February 15, 2031 and $650.0 million of 0.875% convertible senior notes due November 15, 2032, with a 13-day option for up to an additional $100.0 million of each series.
- Initial conversion price of approximately $87.20 per share, a conversion premium of approximately 27.5% above the $68.39 closing price on November 6, 2025.
- Expected net proceeds of approximately $1.274 billion, or approximately $1.47 billion if the option is exercised in full.
- Approximately $1.020 billion of proceeds is expected to fund privately negotiated repurchases of existing 2027 and 2028 convertible notes, with about $1.019 billion in cash expected to be paid including accrued interest.
- Approximately $182.7 million is expected to fund capped call transactions with a cap price of $136.78 per share, a 100% premium to the reference price.
- Notes are senior, unsecured obligations and are convertible into cash and/or shares at the Company's election, with a fundamental change repurchase right at 100% of principal plus accrued interest.
- Offering is being made only to qualified institutional buyers under Rule 144A, and is expected to close on November 12, 2025, subject to customary conditions.
03—Questions
Frequently Asked Questions
What securities did Halozyme price and in what amounts?
Halozyme priced $650.0 million aggregate principal amount of 0% convertible senior notes due 2031 and $650.0 million aggregate principal amount of 0.875% convertible senior notes due 2032. The initial purchasers also received a 13-day option to buy up to an additional $100.0 million of each series.
At what price would the notes convert into common stock?
Both series have an initial conversion rate of 11.4683 shares per $1,000 principal amount, equal to an initial conversion price of approximately $87.20 per share. This represents a conversion premium of approximately 27.5% above the $68.39 closing price on November 6, 2025. The filing states conversion rates are subject to adjustment in some events.
How will Halozyme use the proceeds?
The Company expects net proceeds of approximately $1.274 billion (approximately $1.47 billion if the option is exercised in full). It expects to use about $182.7 million for capped call transactions and about $1.020 billion to repurchase portions of its 2027 and 2028 convertible notes. The remainder is intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and future note repurchases.
How do the capped call transactions affect dilution?
The capped call transactions are generally expected to reduce potential dilution upon conversion and/or offset certain cash payments above principal, when the stock price is above the conversion price. The cap price is initially $136.78 per share, a 100% premium to the $68.39 reference price. Above the cap price, dilution and cash payments would not be offset to the extent the market price exceeds the cap.
Could the transactions affect Halozyme's stock price?
The filing states that the Note Repurchases could increase or reduce the size of any decrease in the market price of the common stock or the Convertible Notes, and could have resulted in a higher effective conversion price. It also notes that hedging activity by noteholders and by option counterparties, including related derivative transactions and share purchases, could affect the stock price.
04—Continue